

Clinical Trial Protocol

Iranian Registry of Clinical Trials

01 Jun 2026

Effect of pentoxifylin on reducing erythropoietin needs in peritoneal dialysis patients with anemia

Protocol summary

Summary

The purpose of this study was evaluation of effect of pentoxifylin on hemoglobin level and erythropoietin dose changing in hemodialysis patients with anemia. This study was done in hemodialysis centers in Isfahan (Zahraye Marziye) and Khomeini Shahr (Saei). Patients who were on hemodialysis for at least one month and without infection or bleeding in the last month were assigned in one of the following groups after full satisfaction of participation in research. The patients received pentoxifylin tablet, 400mg or placebo. Blood levels of Hemoglobin, Iron, Ferritin, serum iron binding capacity, and need to erythropoietin were measured and compared between groups.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201101012417N6**

Registration date: **2011-01-13, 1389/10/23**

Registration timing: **retrospective**

Last update:

Update count: **0**

Registration date

2011-01-13, 1389/10/23

Registrant information

Name

Firouzeh Moeinzadeh

Name of organization / entity

Isfahan University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 31 1625 5555

Email address

moinzade@resident.mui.ac.ir

Recruitment status

Recruitment complete

Funding source

Vice Chancellor for Research, Isfahan University of Medical Sciences

Expected recruitment start date

2009-04-04, 1388/01/15

Expected recruitment end date

2010-09-06, 1389/06/15

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Effect of pentoxifylin on reducing erythropoietin needs in peritoneal dialysis patients with anemia

Public title

Effect of pentoxifylin on reducing erythropoietin needs in peritoneal dialysis patients with anemia

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: patient's satisfaction, hemodialysis for at least 1 month prior to the study, hemoglobin concentration less than 10g/dL in at least 2 episodes, Erythropoietin use more than 12000 units per week, no bleeding over the last month prior to the intervention, no infection resulting admission over the last month prior to the intervention, vitamin C consumption 250mg twice a week Exclusion criteria: drug intolerance, bleeding during the study period, infection resulting admission

Age

From **18 years** old to **90 years** old

Gender

Both

Phase

N/A

Groups that have been masked

No information

Sample size

Target sample size: 50

Randomization (investigator's opinion)

Randomized

Randomization description**Blinding (investigator's opinion)**

Double blinded

Blinding description**Placebo**

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Vice Chancellor for Research, Isfahan University of Medical Sciences

Street address

Isfahan 1000 jarib

City

Isfahan

Postal code**Approval date**

2010-02-20, 1388/12/01

Ethics committee reference number

287028

Health conditions studied**1****Description of health condition studied**

End Stage Renal Disease

ICD-10 code

N18.0

ICD-10 code description

End-stage renal disease

Primary outcomes**1****Description**

serum hemoglobin level

Timepoint

Baseline, monthly, at the end of the study

Method of measurement

g/dL

2**Description**

serum albumin

Timepoint

Baseline, monthly, at the end of the study

Method of measurement

g/dL

3**Description**

Erythropoietin use

Timepoint

monthly

Method of measurement

International unit

Secondary outcomes**1****Description**

serum Iron level

Timepoint

Baseline, 3rd month, at the end of study

Method of measurement

µg/dL

2**Description**

Total iron binding capacity

Timepoint

Baseline, 3rd month, at the end of study

Method of measurement

µg/dL

Intervention groups**1****Description**

Pentoxifylin, 400mg orally daily for 6 months

Category

Treatment - Drugs

2**Description**

Placebo daily for 6 months orally

Category

Placebo

Recruitment centers**1****Recruitment center****Name of recruitment center**

Peritoneal dialysis center. Alzahra hospital

Full name of responsible person

Mrs. Karimi
Street address
Alzahra hospital, Sofe Ave, Isfahan
City
Isfahan

Sponsors / Funding sources

1

Sponsor

Name of organization / entity
Vice Chancellor for Research, Isfahan University of
Medical Sciences
Full name of responsible person
Vice Chancellor for Research
Street address
Hezarjarib, Isfahan
City
Isfahan

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Vice Chancellor for Research, Isfahan University of
Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity
Isfahan University of Medical Science
Full name of responsible person
Dr. Mojgan Mortazavi
Position
Associate Professor of Nephrology
Other areas of specialty/work
Street address
Isfahan University of Medical Sciences
City
Isfahan
Postal code
Phone
+98 31 1668 5555
Fax
Email
m_mortazavi@med.mui.ac.ir
Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity
Isfahan University of Medical Sciences
Full name of responsible person
Dr. Mojgan Mortazavi
Position
Associate Professor of Nephrology
Other areas of specialty/work
Street address
Isfahan University of Medical Sciences
City
Isfahan
Postal code
Phone
+98 31 1668 5555
Fax
Email
m_mortazavi@med.mui.ac.ir
Web page address

Person responsible for updating data

Contact

Name of organization / entity
Isfahan University of Medical Sciences
Full name of responsible person
Dr Firouzeh Moeinzadeh
Position
Assistant Professor of Internal Medicine
Other areas of specialty/work
Street address
Azahra Hospital, Isfahan
City
Isfahan
Postal code
Phone
+98 31 1668 5555
Fax
Email
moinzade@resident.mui.ac.ir
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty